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Objective: To examine the utility of the new Movement Disorder Society (MDS) diagnostic criteria in a
large cohort of Parkinson's disease (PD) patients.
Methods: Recently diagnosed (<3.5 years) PD cases fulﬁlling United Kingdom (UK) brain bank criteria in
Tracking Parkinson's, a UK multicenter prospective natural history study were assessed by retrospective
application of the MDS criteria.
Results: In 2000 cases, 1835 (91.7%) met MDS criteria for PD, either clinically established (n ¼ 1261,
63.1%) or clinically probable (n ¼ 574, 28.7%), leaving 165 (8.3%) not fulﬁlling criteria. Clinically estab-
lished cases were signiﬁcantly more likely to have limb rest tremor (89.3%), a good L-dopa response
(79.5%), and olfactory loss (71.1%), than clinically probable cases (60.6%, 44.4%, and 34.5% respectively),
but differences between probable PD and ‘not PD’ cases were less evident. In cases not fulﬁlling criteria,
the mean MDS UPDRS3 score (25.1, SD 13.2) was signiﬁcantly higher than in probable PD (22.3, SD 12.7,
p ¼ 0.016) but not established PD (22.9, SD 12.0, p ¼ 0.066). The L-dopa equivalent daily dose of 341 mg
(SD 261) in non-PD cases was signiﬁcantly higher than in probable PD (250 mg, SD 214, p < 0.001) and
established PD (308 mg, SD 199, p ¼ 0.025). After 30 months' follow-up, 89.5% of clinically established
cases at baseline remained as PD (established/probable), and 86.9% of those categorized as clinically
probable at baseline remained as PD (established/probable). Cases not fulﬁlling PD criteria had more
severe parkinsonism, in particular relating to postural instability, gait problems, and cognitive
impairment.Ipswich Hospital NHS Trust,
N. Malek et al. / Parkinsonism and Related Disorders 40 (2017) 40e46 41Conclusion: Over 90% of cases clinically diagnosed as early PD fulﬁlled the MDS criteria for PD. Those not
fulﬁlling criteria may have an atypical parkinsonian disorder or secondary parkinsonism that is not
correctly identiﬁed by the UK Brain Bank criteria, but possibly by the new criteria.
© 2017 Published by Elsevier Ltd.1. Introduction
The accurate diagnosis of Parkinson's disease (PD) assists pa-
tient management and healthcare planning, and the identiﬁcation
of effective new treatments, which is important for a disease with
an increasing prevalence [1]. Clinical diagnostic accuracy is sub-
optimal, being around 80% based on an overview of 11 studies [2]
[3]. As there is no biomarker or speciﬁc imaging test for PD, the
diagnosis relies heavily on clinical assessment [4]. Increased
knowledge about PD and disorders that mimic it has allowed the
development of new clinical Movement Disorder Society (MDS)
diagnostic criteria [4]. These retain the core deﬁnition of parkin-
sonism (bradykinesia, rigidity and/or rest tremor) but do not allow
for postural instability, compared to the United Kingdom (UK) Brain
Bank criteria [5]. After conﬁrmation of parkinsonism, a clinical
diagnosis of PD according to the MDS criteria is based on: absolute
exclusion criteria (which rule out PD), red ﬂags (which must be
counterbalanced by supportive criteria), and positive supportive
criteria. These are combined to determine diagnostic certainty as
clinically probable PD, or clinically established PD [4]. The new
consensus criteria represent a summation of available knowledge,
but have not been tested prospectively, which was the purpose of
the current study. We classiﬁed and described the phenotype of
cases recruited to an observational study of PD, according to
fulﬁlment of the new MDS criteria [4].2. Methods
Patients were recruited to Tracking Parkinson's, a large pro-
spective, UK multicenter project, as detailed elsewhere [6]. In brief,
recent onset PD cases with a clinical diagnosis and fulﬁlling UK
Brain Bank criteria at study entry [5] were recruited, including
drug-naïve and treated patients. Those with severe comorbid
illness, other degenerative parkinsonism, symmetrical lower body
parkinsonism, drug-induced parkinsonism, or a clinical diagnosis of
dementia at ﬁrst assessment were excluded. Levodopa (L-dopa)
equivalent daily doses (LEDD) were calculated using an established
formula [7]. Motor subtypes were determined by established
methods [8]. Montreal cognitive assessment (MoCA) scores were
adjusted for years of education and categorized as normal (>23),
mild cognitive impairment (MCI) (22e23, or less than 22 but
without functional impairment), or dementia (21 or less with
functional impairment) [9]. Olfaction testing used either the 40-
item University of Pennsylvania Smell Identiﬁcation Test (UPSIT)
or Snifﬁn’ Sticks 16-item version (SS), and hyposmia was deﬁned as
previously reported [10]. FP-CIT scanning was performed as part of
routine care, on the basis of diagnostic uncertainty.
As the MDS diagnostic criteria were published after patient
recruitment was complete, the criteria were applied retrospec-
tively. Each component wasmapped to the assessments performed,
including MDS UPDRS, lying and standing blood pressure, response
to L-dopa test dose, non-motor symptom scales, scales for outcome
in autonomic symptoms in PD, PD and Epworth sleep score, and
questionnaires for wearing off, rapid eye movement behavior dis-
order, constipation, Leeds anxiety and depression, and PD quality of
life. Clinicians assessed each case, at baseline (study entry) andafter 1 and 2.5 years, for any unusual or atypical features for PD,
under several categories: clinical presentation, symptoms, signs,
disease course, or therapy response. To ensure that early signs were
not overlooked, such features were notedwhen they ‘could indicate
an alternative diagnosis to PD (i.e. idiopathic parkinsonismwith the
presence of Lewy bodies in the substantia nigra), no matter how
remote’. Clinicians also rated their clinical diagnostic certainty be-
tween 0% (not PD) and 100% (deﬁnite PD).
There was some variance in the data elements collected,
compared to the MDS criteria: we recorded vertical gaze palsy
(rather than only downward vertical gaze palsy), and did not spe-
ciﬁcally note recurrent falls, inspiratory stridor, or frequent inspi-
ratory sighs. We assessed for the absence of an observable L-dopa
response followingMDS criteria (daily L-dopa dose 600mg ormore,
and bradykinesia or rigidity in at least one body part exceeding 2
points), and carried out an additional exploratory analysis (no L-
dopa dose threshold, MDS UPDRS 3 score above 20 to deﬁne at least
moderate disease, and clinician assessment of ‘little or no response
to L-dopa or a dopamine agonist’). For assessment of a clear and
dramatic response to dopaminergic therapy, we used an improve-
ment of over 30% in MDS UPDRS 3 after the patient's usual morning
L-dopa dose, taken after a practically deﬁned overnight period off
medication.
2.1. Statistical analysis
Regression models were used to test the association between
the three MDS classiﬁcation groups and clinical features. Clinical
characteristics were the dependent variables and the MDS criteria
groups (along with age, gender and disease duration) were the
independent variables. Regression was linear for continuous out-
comes, logistic for binary outcomes, ordinal (also called propor-
tional odds) for ordinal outcomes (MoCA and Hoehn and Yahr
stage), and multinomial for motor subtype (using tremor dominant
as the baseline category). Two-way p-values across the three MDS
classiﬁcation groups were calculated as 2-tailed, after adjustment
for three confounders: age, gender and disease duration. The
linearity of age and disease duration was tested using fractional
polynomials in univariate models, and then transformed if non-
linear. The results were not corrected for multiple comparisons.
The agreement between baseline and follow-up categorization was
tested using weighted kappa, and also, because of imbalance of
group sizes and numbers of cases changing category, by the
weighted Gwet AC1/AC2 coefﬁcient [11,12]. Statistical analysis was
conducted using STATA (version 14, StataCorp, Texas, USA).
3. Results
There were 2000 cases at study entry, mean age 64.4 years (SD
9.8), disease duration 1.3 years (SD 0.9), and 64.9% were male. 1835
(91.7%) met the MDS diagnostic criteria for PD, either clinically
established (n ¼ 1261, 63.1% of all cases) or clinically probable
(n ¼ 574, 28.7% of all cases), leaving 165 (8.3% of all cases) who did
not meet criteria (Table 1). Tremor as a symptom at onset was
signiﬁcantly more prevalent in clinically established PD (83.3%)
than clinically probable PD (57.4%), or those not fulﬁlling criteria for
Table 1
Demographic and disease features in 2000 cases with a clinical diagnosis of recent onset Parkinson's disease, categorized according to fulﬁlment of MDS diagnostic criteria for
PD.
Characteristic
All cases
N ¼ 2000
(100%)
Fulﬁlment of MDS criteria for PD Adjusted p-values
Not PD
N ¼ 165
(8.3%)
Clinically
probable
N ¼ 574
(28.7%)
Clinically
established
N ¼ 1261
(63.1%)
Not PD vs Clinically
probable
Not PD vs Clinically
established
Clinically probable vs Clinically
established
Age at onseta 64.4 (9.8) 64.7 (9.7) 65.2 (9.9) 64.0 (9.7) 0.61f 0.39f 0.021f
Age at diagnosisa 66.2 (9.3) 66.5 (9.0) 67.1 (9.4) 65.8 (9.3) 0.49f 0.41f 0.010f
Age at baselinea 67.6 (9.3) 67.8 (9.0) 68.3 (9.4) 67.2 (9.3) 0.49f 0.41f 0.010f
Disease durationa 1.3 (0.9) 1.4 (0.9) 1.2 (0.9) 1.4 (0.9) 0.084g 0.77g <0.00g
Gender (Male)b 1299
(64.9%)
104
(63.0%)
369 (64.3%) 826 (65.5%) 0.80h 0.51h 0.52h
Symptoms at onset
Tremorb 1452
(74.4%)
102
(62.6%)
310 (57.4%) 1040 (83.3%) 0.19i <0.001i <0.001i
Rigidityb 1337
(71.9%)
114
(76.0%)
365 (70.1%) 858 (72.2%) 0.15i 0.32i 0.37i
Bradykinesiab 1493
(78.5%)
128
(81.5%)
411 (77.1%) 954 (78.7%) 0.21i 0.43i 0.35i
Postural
instabilityb
364
(19.8%)
48
(31.0%)
114 (22.0%) 202 (17.4%) 0.012i <0.001i 0.083i
Motor Subtypec
Tremor
Dominant
832
(45.9%)
46
(31.3%)
210 (41.3%) 576 (49.8%)
PIGD 745
(41.1%)
86
(58.5%)
244 (47.9%) 415 (35.9%) 0.022i <0.001i <0.001i
Indeterminate 236
(13.0%)
15
(10.2%)
55 (10.8%) 166 (14.3%) 0.54i 0.69i 0.65i
MoCAd
Normal 1342
(73.2%)
100
(65.8%)
386 (74.1%) 856 (73.7%) 0.013i 0.020i 0.59i
MCI 227
(12.4%)
19
(12.5%)
54 (10.4%) 154 (13.3%)
Dementia 265
(14.4%)
33
(21.7%)
81 (15.5%) 151 (13.0%)
MDS UPDRS 3a 22.9 (12.3) 25.1
(13.2)
22.3 (12.7) 22.9 (12.0) 0.016i 0.066i 0.22i
Hoehn and Yahre
0e1.5 948
(47.9%)
69
(41.8%)
283 (50.8%) 596 (47.4%) 0.063i 0.25i 0.18i
2e2.5 894
(45.2%)
69
(41.8%)
239 (42.9%) 586 (46.6%) <0.001i <0.001i 0.72i
3 þ 137 (6.9%) 27
(16.4%)
35 (6.3%) 75 (6.0%)
Untreatedb 196 (9.8%) 17
(10.3%)
92 (16.1%) 87 (6.9%) 0.11i 0.12i <0.001i
LEDD (mg per
day)a
294 (211) 341 (261) 250 (214) 308 (199) <0.001i 0.025i <0.001i
Data are shown as mean and standard deviation or n%. MDS¼Movement Disorder Society, PD¼ Parkinson's disease, UPDRS 3¼ Uniﬁed Parkinson's disease rating scale Part 3,
LEDD ¼ levodopa equivalent daily dose, PIGD ¼ postural instability and gait difﬁculty, MoCA ¼ Montreal Cognitive Assessment.
a Linear regression.
b Logistic regression.
c Multinomial regression.
d Proportional odds regression.
e Partial proportional odds regression (failed proportional odds assumption for MDS criteria groups).
f Adjusted for sex and disease duration.
g Adjusted for age and sex.
h Adjusted for age and disease duration.
i Adjusted for sex, age and disease duration.
N. Malek et al. / Parkinsonism and Related Disorders 40 (2017) 40e4642PD (62.6%), both p < 0.001, and the proportion with a tremor
dominant motor subtype followed the same pattern (Table 1).
Cognition was worse in non-PD cases (21.7% dementia) compared
to 15.5% dementia in clinically probable PD cases (p ¼ 0.013) and
13.0% dementia in clinically established PD cases (p ¼ 0.02). The
MDS UPDRS 3 score was very similar for clinically established (22.9,
SD 12.0) and clinically probable PD cases (22.3, SD 12.7), but wassigniﬁcantly higher in cases not fulﬁlling PD (25.1 SD 13.2, p¼ 0.016
compared to clinically probable PD). The LEDD in the cases failing to
meet MDS criteria for PD was 341 mg (SD 261), which was signif-
icantly higher than those with clinically probable PD (250 mg, SD
214, p < 0.001), and in those with clinically established PD (308 mg,
SD 199, p ¼ 0.025).
The numbers of red ﬂags, supporting criteria, and absolute
N. Malek et al. / Parkinsonism and Related Disorders 40 (2017) 40e46 43exclusions categorized by MDS diagnostic group are in Table 2.
Most non-PD cases were categorized on the basis of one or more
absolute exclusion (149 of 165 cases, 90.3%), rather than having an
excess of red ﬂags over supporting features (15 of 165, 9.1%), or
having >2 red ﬂags (1 of 165, 0.6%). In these non-PD cases, the most
common exclusion criteria were vertical gaze palsy (n ¼ 117, 70.9%
of cases not meeting PD criteria, or 5.8% of all cases) and cerebellar
features (n¼ 25,15.2% of cases notmeeting PD criteria, or 1.3% of all
cases). Only 3 cases (0.2%) were excluded (and thereby categorized
as non-PD) on the basis of an absent L-dopa response deﬁned by the
MDS criteria. However, using our alternative deﬁnition (at least
moderate disease and subjectively absent or poor dopaminergic
therapy response), 72 cases (3.6%) were categorized as non-PD,
which increased the proportion of non-PD cases from 8.3% to 11.2%.
Considering the positive supportive MDS criteria, these were
most prevalent in clinically established PD, and were considerably
lower in clinically probable PD, but intermediate in those not
meeting PD criteria (Table 2). Red ﬂags were present in 288 of the
2000 cases (14.4%), of which the majority (234 cases, 81.3% of 288)
were categorized as clinically probable PD (rather than non-PD)
because of supportive features, reﬂecting the balancing approachTable 2
Fulﬁlment of MDS criteria in 2000 cases with a clinical diagnosis of recent onset Parkins
Characteristic All cases
N ¼ 2000 (100%)
F
N
N
Number of red ﬂags
0 1712 (85.6%) 1
1 251 (12.6%) 4
2 36 (1.8%) 1
>2 1 (0.1%) 1
Number of supporting criteria
0 55 (2.8%) 1
1 387 (19.4%) 4
2 874 (43.7%) 6
>2 684 (34.2%) 4
Number of absolute exclusion criteria
0 1851 (92.6%) 1
1 143 (7.2%) 1
>1 6 (0.3%) 6
Red ﬂags
Rapid gait progression 3 (0.2%) 0
Absence of motor progression 0 (0.0%) 0
Bulbar dysfunction 115 (5.8%) 2
Respiratory dysfunction 0 (0.0%) 0
Severe autonomic 148 (7.4%) 2
Recurrent falls 0 (0.0%) 0
Disproportionate anterocollis 0 (0.0%) 0
Common non-motor absent 0 (0.0%) 0
Pyramidal signs 36 (1.8%) 9
Symmetric parkinsonism 24 (1.2%) 5
Supporting criteria
Clear L-dopa response 1363 (68.2%) 1
L-dopa induced dyskinesia 94 (4.7%) 7
Rest tremor of a limb 1585 (79.3%) 1
Olfactory loss 1181 (59.0%) 8
Absolute exclusion criteria
Unequivocal cerebellar 25 (1.3%) 2
Vertical gaze palsy 117 (5.8%) 1
Fronto-temporal dementia/PPA 0 (0.0%) 0
Parkinsonism in lower limbs only 1 (0.1%) 1
Dopamine blocker/depleter 2 (0.1%) 2
Absence of L-dopa response 3 (0.2%) 3
Cortical sensory loss/apraxia 8 (0.4%) 8
Normal functional dopamine imaging 0 (0.0%) 0
Alternative parkinsonism documented 0 (0.0%) 0
MDS ¼ Movement Disorder Society, PD ¼ Parkinson's disease, PPA ¼ Primary progressivin the MDS criteria [4] (Table 2). There were 2 positive supportive
criteria in 56.9% of the 1261 clinically established PD cases, and
more than 2 such criteria in 43.1% of these cases. These supportive
criteria were less common in clinically probable PD (2 criteria in
16.0%, more than 2 criteria 16.7%), but were intermediate in those
categorized as non-PD (2 criteria in 39.4%, more than 2 criteria in
26.7%).
After a mean follow-up of 2.5 (SD 0.6) years, the categorization
of cases by MDS criteria as PD versus not PD was largely stable,
compared to the baseline categorization (Table 3). Out of 165 non-
PD at baseline, 156 (94.5%) remained as non-PD, and 9 (5.5%) were
categorized as probable PD because of emergent supportive fea-
tures, which balanced red ﬂags. Clinically probable PD became
clinically established PD due to the increased supporting features
(to 2 or more) without any red ﬂags (147 of 574 cases, 25.6%). Of the
1261 clinically established PD cases at baseline, 152 (12.1%) became
clinically probable PD at follow-up, due to red ﬂags emerging.
Clinically probable PD cases at baseline remained probable, or
became established, in 86.9% of cases. Clinically established PD
cases at baseline remained established PD, or became clinically
probable PD, in 89.5%. The number of cases categorized as not PDon's disease.
ulﬁlment of MDS criteria for Parkinson's disease
ot PD
¼ 165 (8.3%)
Clinically probable
N ¼ 574 (28.7%)
Clinically established
N ¼ 1261 (63.1%)
11 (67.3%) 340 (59.2%) 1261 (100%)
1 (24.8%) 210 (36.6%) Not applicable
2 (7.3%) 24 (4.2%) Not applicable
(0.6%) 0 (0.0%) Not applicable
3 (7.9%) 42 (7.3%) Not applicable
3 (26.1%) 344 (59.9%) Not applicable
5 (39.4%) 92 (16.0%) 717 (56.9%)
4 (26.7%) 96 (16.7%) 544 (43.1%)
6 (9.7%) 574 (100.0%) 1261 (100%)
43 (86.7%) Not applicable Not applicable
(3.6%) Not applicable Not applicable
(0.0%) 3 (0.5%) Not applicable
(0.0%) 0 (0.0%) Not applicable
9 (17.6%) 86 (15.0%) Not applicable
(0.0%) 0 (0.0%) Not applicable
5 (15.2%) 123 (21.4%) Not applicable
(0.0%) 0 (0.0%) Not applicable
(0.0%) 0 (0.0%) Not applicable
(0.0%) 0 (0.0%) Not applicable
(5.5%) 27 (4.7%) Not applicable
(3.0%) 19 (3.3%) Not applicable
05 (63.6%) 255 (44.4%) 1003 (79.5%)
(4.2%) 22 (3.8%) 65 (5.2%)
11 (67.3%) 348 (60.6%) 1126 (89.3%)
7 (52.7%) 198 (34.5%) 896 (71.1%)
5 (15.2%) Not applicable Not applicable
17 (70.9%) Not applicable Not applicable
(0.0%) Not applicable Not applicable
(0.6%) Not applicable Not applicable
(1.2%) Not applicable Not applicable
(1.8%) Not applicable Not applicable
(4.8%) Not applicable Not applicable
(0.0%) Not applicable Not applicable
(0.0%) Not applicable Not applicable
e aphasia.
Table 3
Stability of MDS categorization of Parkinson's disease, comparing baseline and 2.5 years' follow-up.
Baseline analysis Follow-up analysis
Not PD Probable PD Established PD % probable or established PD
Not PD
N ¼ 165
156 9 0 5.5%
Probable PD
N ¼ 574
75 352 147 86.9%
Established PD
N ¼ 1261
133 152 976 89.5%
MDS ¼ Movement Disorder Society, PD ¼ Parkinson's disease.
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The overall percent agreement comparing categorization at base-
line to follow-up was 74.2% (actual), or 83.8% (weighted). The
weighted Kappa was 0.55, while the weighted Gwet AC1/AC2 was
0.70.
During follow-up, 31 cases had a change in clinical diagnosis, of
which 21 cases were: MSA (n¼ 6), PSP (n¼ 5), essential or dystonic
tremor (n ¼ 3), vascular parkinsonism (n ¼ 2), and single cases of
corticobasal degeneration, functional parkinsonism, multiple scle-
rosis, post-polio syndrome, and spinal cord compression (Suppl
Table 1). The 10 remaining cases had inconclusive diagnoses: 4 with
normal presynaptic dopaminergic functional imaging performed
after study entry, and 6 not otherwise speciﬁed. Of the 31 cases
with a revised diagnosis, 5 (16.1%) had been classiﬁed as non-PD by
MDS criteria at baseline, which increased to 11 (35.5%) at follow-
up; 12 (38.7%) were classiﬁed as clinically probable PD at base-
line, which declined to 8 (25.8%) at follow-up; and 14 (45.2%) were
classiﬁed as clinically established PD at baseline, which declined to
12 (38.7%) at follow-up.
The clinicians' assessment reported atypical clinical features
that might raise diagnostic doubt in 181 cases (9.1%), and this was
more common in cases categorized as non-PD by the MDS criteria
(15.8%), compared to 12.0% in clinically probable cases, and 6.8% in
clinically established cases. Clinicians rated the diagnostic certainty
of PD at less than 90% in 521 cases (26.1%); 29.7% of the MDS non-
PD cases had this <90% diagnostic certainty score, compared to
33.3% of those classiﬁed as clinically probable PD, and 22.3% of
clinically established PD.
4. Discussion
Our study is the ﬁrst to apply the new MDS diagnostic criteria
for PD to a large scale cohort. We found that over 90% of patients, at
an early disease stage and with cardinal motor features and a
clinical diagnosis of PD, fulﬁlled the MDS criteria for PD at baseline
(study entry), and a higher proportion was categorized as clinically
established PD (more than 60%) than clinically probable PD (less
than 30%). In our cohort, the MDS diagnostic criteria are therefore
at least 90% sensitive compared to the most commonly used pre-
ceding criteria [5]. We found that categorization as not PD (under
10%) resulted almost exclusively from the presence of absolute
exclusion criteria, rather than having more than 2 diagnostic red
ﬂags (only 1 case). Also, baseline categorization as ‘not PD’ affected
one quarter of 31 cases with a later revised diagnosis, and this ‘not
PD’ status increased to over 40% of these 31 cases at 2.5 years.
There were signiﬁcant phenotypic differences between clini-
cally established and clinically probable PD cases. Clinically estab-
lished PD cases had more supporting diagnostic features than
clinically probable PD cases, indicating that, when red ﬂags are
present, there are also fewer supporting criteria (by deﬁnition all
clinically established PD cases have 2 or more supporting criteria;only around one third of clinically probable PD have 2 or more
supporting criteria). Since rest tremor is one of the 4 supporting
criteria, clinically established PD cases were therefore more likely
to be tremor dominant, and less likely to have postural instability
gait difﬁculty (PIGD) [8]. Clinically established PD cases were also
more likely to have commenced anti-parkinsonian medication, and
were prescribed higher doses of dopaminergic therapy (around 25%
greater than clinically probable cases).
Given the critical signiﬁcance of dopaminergic responsiveness
to diagnostic accuracy [2,3], both the supporting feature of a clear
and dramatic response to dopaminergic therapy, and the absolute
exclusion of an absent observable L-dopa response, are of particular
importance. A good L-dopa response was present in those classiﬁed
as clinically established PD (around 80%), but a signiﬁcant propor-
tion of cases (almost two-thirds) classiﬁed as non-PD also showed a
good L-dopa response. This may reﬂect the known early-stage
dopa-responsiveness in disorders such as PSP [13,14] and MSA
[15], which wanes over time. Absence of the L-dopa response by
MDS criteria involved very few cases (0.2%), largely because the
required daily L-dopa dose of at least 600 mg for this criterion was
rare at this early disease stage. Our exploratory more inclusive
deﬁnition of poor dopaminergic responsiveness identiﬁed more
cases and increased the proportion of non-PD cases by around 3%.
We will test whether this is a useful early indicator of a diagnosis
other than PD during further follow-up.
We also found that disease severity was signiﬁcantly greater for
cases categorized as non-PD compared to PD cases, including worse
motor severity, more cases with PIGD, and more cases with de-
mentia. This replicates the baseline features in the 8.1% of 800 cases
who entered the DATATOP study as PD but later underwent diag-
nostic revision to ‘not PD’, during 6 years mean follow-up [16]. In
addition, the dopaminergic therapy dose was greater in ‘not PD’
cases using the MDS criteria. The cases identiﬁed byMDS criteria as
atypical for PD therefore havemore severe parkinsonism that is less
responsive to dopaminergic therapy, suggesting that a majority of
such cases have an atypical parkinsonian syndrome or comorbidity
(e.g. cerebrovascular disease) [17,18].
The proportion of cases with a revised diagnosis during follow-
up (1.6%) was considerably lower than the number of cases cate-
gorized either at baseline (8.3%) or after follow-up (18.2%) as non-
PD by MDS criteria. However, our clinicians much more
frequently recognized atypical features (9.1% of cases at baseline),
suggesting that diagnostic revision is delayed until atypical features
are more deﬁnite. However, clinical trials of emerging treatments,
targeted to either abnormal alpha-synuclein or tau protein accu-
mulation, would beneﬁt from earlier distinction of these disorders.
Our ﬁndings suggest that distinguishing features are present even
at this relatively early stage, which is consistent with one previous
long-duration clinical and autopsy study, in which early diagnostic
clues were followed by deﬁnitive features, which improved the
clinical accuracy (which was higher for PSP than for MSA) [19].
N. Malek et al. / Parkinsonism and Related Disorders 40 (2017) 40e46 45The new MDS diagnostic criteria set targets for accurate case
identiﬁcation: 90% of clinically established cases should have Lewy
body associated PD, and 80% of clinically probable cases [4]. As an
indicator of this, we found the diagnostic PD categories to be stable:
cases in both established and probable groups retained a PD cate-
gorization of around 85% after 2.5 years. However, within the PD
groups, there was movement in both directions (around 1 in 10
clinically established cases became clinically probable, and around
a quarter of clinically probable cases became clinically established).
This helps to quantify the likelihood of emerging red ﬂags, and the
development of increased numbers of supporting features, both of
which are central to the MDS criteria deﬁnitions. We also found
support for a further aim of the MDS diagnostic criteria: that only
3% of cases categorized as non-PD would actually have PD [4]. We
found that 7 cases (3.1%) changed category from not PD to clinically
probable PD, because of the emergence of additional supporting
features; the long-term validity of these observations will be tested
in follow-up.
Rest tremor is one of the cardinal motor signs of parkinsonism
[20], and one of 4 supporting features for PD, when present in a
limb, in theMDS criteria [4]. However, rest tremor can be present in
dystonia [21], essential tremor [22], PSP [23], MSA [24], functional
disorders [25] and after stroke [26]. Rest tremor was not speciﬁc for
PD (possible or probable) in one autopsy study [2]. In our cohort,
limb rest tremor was common (around 70% of cases) in ‘not PD’
cases, against around 60% of clinically probable cases (although in
clinically established PD it was almost 90%). Accordingly the MDS
criteria help to emphasise the importance of other clinical features
(red ﬂags and exclusions) that are inconsistent with a diagnosis of
PD.
There are certain limitations to our study design. As the MDS
criteria were published after our study completed patient recruit-
ment, their application was retrospective, and there were some
variations in deﬁnitions. By recording vertical gaze palsy, rather
than downgaze palsy only, the accuracy of these observations is less
than optimal, and the number of cases categorized as non-PD may
be increased. Our objective measure of L-dopa responsiveness was
based on the patient's usual morning L-dopa dose, which differs
from the response after a change in medication deﬁned by the MDS
criteria. In addition, we did not have data regarding recurrent falls,
inspiratory stridor, or disproportionate anterocollis, or results of
imaging cardiac sympathetic denervation (although this is rarely
applied), so we may have slightly overestimated clinically probable
PD cases. We do not have autopsy data, but enrolment to the Par-
kinson's UK Brain Bank is a component of our study, so this will
become available in future.
In conclusion, the MDS criteria for PD are useful for corrobo-
rating the diagnosis of PD, amongst cases fulﬁlling the core deﬁ-
nition of parkinsonism and with a clinical PD diagnosis, and helpful
in categorizing levels of diagnostic certainty. Cases not fulﬁlling
MDS diagnostic criteria for PD have more severe parkinsonism, in
particular relating to postural instability, gait problems, and
cognitive impairment.Author contributions
NM: Data collection, analysis, manuscript writing and editing.
ML: Data analysis, manuscript writing and editing.
NB, RAB, DJB, HRM: Data collection, study design, manuscript
editing.
JH, NW, NW: Study design.
YBS: Study design, data analysis plan, manuscript editing.
KAG, DGG: Study design, data collection, analysis, manuscript
writing and editing.Financial disclosures
NMalek, KA Grosset, MA Lawton, NWilliams, Y Ben-Shlomo: No
conﬂicts of interest.
N Bajaj has received payment for advisory board attendance
from UCB, Teva Lundbeck, Britannia, GSK, Boehringer, honoraria
from UCB Pharma, GE Healthcare, Lily Pharma, Medtronic and an
unrestricted educational grant from GE Healthcare.
RA Barker has received grants from Parkinson's UK, NIHR, Cure
Parkinson's Trust, Evelyn Trust, Rosetrees Trust, MRC and EU along
with payment for advisory board attendance from Oxford Bio-
medica and LCT, and honoraria from Lilley, Wiley and Springer.
DJ Burn has received grants from NIHR, Wellcome Trust, Glax-
oSmithKline Ltd, Parkinson's UK, and Michael J Fox Foundation. He
has acted as consultant for GSK.
J Hardy has received honoraria from Eisai, and grant support
from MRC/Wellcome, Parkinson's UK, and the Michael J Fox
Foundation.
H R Morris has received grants from Medical Research Council
UK, Wellcome Trust, Parkinson's UK, Ipsen Fund, Motor Neurone
Disease Association, Welsh Assembly Government, PSPAssociation,
CBD Solutions and Drake Foundation, and payment for advisory
board attendance and lectures from Teva, AbbVie, Boehringer
Ingelheim, and GSK.
DG Grosset has received payment for advisory board attendance
from AbbVie, and honoraria from UCB Pharma, GE Healthcare,
Civitas, and Acorda.
Acknowledgements
The research was funded by Parkinson’s UK and supported by
the National Institute for Health Research (NIHR) DeNDRoN
network, the NIHR Newcastle Biomedical Research Unit based at
Newcastle upon Tyne Hospitals NHS Foundation Trust and New-
castle University, and the NIHR funded Biomedical Research Centre
in Cambridge. The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.parkreldis.2017.04.006.
References
[1] E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway,
K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schiﬁtto, A. Siderowf, C.M. Tanner,
Projected number of people with Parkinson disease in the most populous
nations, 2005 through 2030, Neurology 68 (5) (2007) 384e386.
[2] C.H. Adler, T.G. Beach, J.G. Hentz, H.A. Shill, J.N. Caviness, E. Driver-Dunckley,
M.N. Sabbagh, L.I. Sue, S.A. Jacobson, C.M. Belden, B.N. Dugger, Low clinical
diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic
study, Neurology 83 (5) (2014) 406e412.
[3] G. Rizzo, M. Copetti, S. Arcuti, D. Martino, A. Fontana, G. Logroscino, Accuracy
of clinical diagnosis of Parkinson disease: a systematic review and meta-
analysis, Neurology 86 (6) (2016) 566e576.
[4] R.B. Postuma, D. Berg, M. Stern, W. Poewe, C.W. Olanow, W. Oertel, J. Obeso,
K. Marek, I. Litvan, A.E. Lang, G. Halliday, C.G. Goetz, T. Gasser, B. Dubois,
P. Chan, B.R. Bloem, C.H. Adler, G. Deuschl, MDS clinical diagnostic criteria for
Parkinson's disease, Mov. Disord. 30 (12) (2015) 1591e1601.
[5] A.J. Hughes, S.E. Daniel, A.J. Lees, Improved accuracy of clinical diagnosis of
Lewy body Parkinson's disease, Neurology 57 (8) (2001) 1497e1499.
[6] N. Malek, D.M. Swallow, K.A. Grosset, M.A. Lawton, S.L. Marrinan, A.C. Lehn,
C. Bresner, N. Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie, J. Hardy,
H.R. Morris, N.M. Williams, N. Wood, D.G. Grosset, Tracking Parkinson's: study
design and baseline patient data, J. Parkinson's Dis. 5 (4) (2015) 947e959.
[7] C.L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, C.E. Clarke, Systematic re-
view of levodopa dose equivalency reporting in Parkinson's disease, Mov.
Disord. 25 (15) (2010) 2649e2653.
[8] G.T. Stebbins, C.G. Goetz, D.J. Burn, J. Jankovic, T.K. Khoo, B.C. Tilley, How to
identify tremor dominant and postural instability/gait difﬁculty groups with
N. Malek et al. / Parkinsonism and Related Disorders 40 (2017) 40e4646the movement disorder society uniﬁed Parkinson's disease rating scale:
comparison with the uniﬁed Parkinson's disease rating scale, Mov. Disord. 28
(5) (2013) 668e670.
[9] M. Emre, D. Aarsland, R. Brown, D.J. Burn, C. Duyckaerts, Y. Mizuno, G.A. Broe,
J. Cummings, D.W. Dickson, S. Gauthier, J. Goldman, C. Goetz, A. Korczyn,
A. Lees, R. Levy, I. Litvan, I. McKeith, W. Olanow, W. Poewe, N. Quinn,
C. Sampaio, E. Tolosa, B. Dubois, Clinical diagnostic criteria for dementia
associated with Parkinson's disease, Mov. Disord. 22 (12) (2007) 1689e1707
quiz 1837.
[10] M. Lawton, M.T. Hu, F. Baig, C. Ruffmann, E. Barron, D.M. Swallow, N. Malek,
K.A. Grosset, N. Bajaj, R.A. Barker, N. Williams, D.J. Burn, T. Foltynie,
H.R. Morris, N.W. Wood, M.T. May, D.G. Grosset, Y. Ben-Shlomo, Equating
scores of the university of Pennsylvania smell identiﬁcation test and snifﬁn'
sticks test in patients with Parkinson's disease, Park. Relat. Disord. 33 (2016)
96e101.
[11] A.R. Feinstein, D.V. Cicchetti, High agreement but low kappa: I. the problems
of two paradoxes, J. Clin. Epidemiol. 43 (6) (1990) 543e549.
[12] K.L. Gwet, Computing inter-rater reliability and its variance in the presence of
high agreement, Br. J. Math. Stat. Psychol. 61 (Pt 1) (2008) 29e48.
[13] D.R. Williams, I. Litvan, Parkinsonian Syndromes, Continuum (Minneapolis,
Minn.) 19(5 Movement Disorders), 2013, pp. 1189e1212.
[14] D.R. Williams, R. de Silva, D.C. Paviour, A. Pittman, H.C. Watt, L. Kilford,
J.L. Holton, T. Revesz, A.J. Lees, Characteristics of two distinct clinical pheno-
types in pathologically proven progressive supranuclear palsy: Richardson's
syndrome and PSP-parkinsonism, Brain 128 (Pt 6) (2005) 1247e1258.
[15] C. Starhof, L. Korbo, C.F. Lassen, K. Winge, S. Friis, Clinical features in a Danish
population-based cohort of probable multiple system atrophy patients, Neu-
roepidemiology 46 (4) (2016) 261e267.
[16] J. Jankovic, A.H. Rajput, M.P. McDermott, D.P. Perl, The evolution of diagnosis
in early Parkinson disease. Parkinson Study Group, Arch. Neurol. 57 (3) (2000)
369e372.
[17] N. Malek, M.A. Lawton, D.M. Swallow, K.A. Grosset, S.L. Marrinan, N. Bajaj,
R.A. Barker, D.J. Burn, J. Hardy, H.R. Morris, N.M. Williams, N. Wood, Y. Ben-Shlomo, D.G. Grosset, Vascular disease and vascular risk factors in relation to
motor features and cognition in early Parkinson's disease, Mov. Disord. 31
(10) (2016) 1518e1526.
[18] D.M. Swallow, M.A. Lawton, K.A. Grosset, N. Malek, J. Klein, F. Baig,
C. Ruffmann, N.P. Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie,
H.R. Morris, N. Williams, N.W. Wood, M.T. Hu, D.G. Grosset, Statins are un-
derused in recent-onset Parkinson's disease with increased vascular risk:
ﬁndings from the UK Tracking Parkinson's and Oxford Parkinson's Disease
Centre (OPDC) discovery cohorts, J. Neurol. Neurosurg. Psychiatry 87 (11)
(2016) 1183e1190.
[19] A.H. Rajput, B. Rozdilsky, A. Rajput, Accuracy of clinical diagnosis in
parkinsonismea prospective study, Can. J. Neurol. Sci. 18 (3) (1991) 275e278.
[20] A.J. Hughes, S.E. Daniel, S. Blankson, A.J. Lees, A clinicopathologic study of 100
cases of Parkinson's disease, Arch. Neurol. 50 (2) (1993) 140e148.
[21] A.F. Gigante, A. Berardelli, G. Defazio, Rest tremor in idiopathic adult-onset
dystonia, Eur. J. Neurol. 23 (5) (2016) 935e939.
[22] O. Cohen, S. Pullman, E. Jurewicz, D. Watner, E.D. Louis, Rest tremor in pa-
tients with essential tremor: prevalence, clinical correlates, and electro-
physiologic characteristics, Arch. Neurol. 60 (3) (2003) 405e410.
[23] G. Respondek, M. Stamelou, C. Kurz, L.W. Ferguson, A. Rajput, W.Z. Chiu,
J.C. van Swieten, C. Troakes, S. Al Sarraj, E. Gelpi, C. Gaig, E. Tolosa, W.H. Oertel,
A. Giese, S. Roeber, T. Arzberger, S. Wagenpfeil, G.U. Hoglinger, The pheno-
typic spectrum of progressive supranuclear palsy: a retrospective multicenter
study of 100 deﬁnite cases, Mov. Disord. 29 (14) (2014) 1758e1766.
[24] C. Kaindlstorfer, R. Granata, G.K. Wenning, Tremor in Multiple System Atrophy
- a Review, Tremor and Other Hyperkinetic Movements (New York, N.Y.) vol.
3, 2013.
[25] J.I. Sage, M.H. Mark, Psychogenic parkinsonism: clinical spectrum and diag-
nosis, Ann. Clin. Psychiatry 27 (1) (2015) 33e38.
[26] F. Alarcon, J.C.M. Zijlmans, G. Due~nas, N. Cevallos, Post-stroke movement
disorders: report of 56 patients, J. Neurol. Neurosurg. Psychiatry 75 (11)
(2004) 1568e1574.
